Kenneth A. Clark serves as general counsel to companies and their boards of directors, primarily in the biotechnology industry. Ken has extensive expertise in partnering and strategic transactions, having negotiated more than 100 major strategic alliance and M&A transactions.
He also regularly represents companies in financings, spin-outs, and related matters.Ken served on the firm’s board of directors from 2011 to 2014 and from 2002 to 2006, and previously was a member of the firm’s Policy Committee.
He was recognized by Chambers and Partners in its 2005-2018 editions of Chambers USA: America’s Leading Lawyers for Business as one of the country’s top biotechnology lawyers, being identified as “Band One” in the biotechnology field. Ken served as a director of Pharmacyclics, Inc. (NASDAQ: PCYC) from 2012 until their sale to AbbVie in 2015.
- J.D., University of Texas School of Law
- B.A., Vanderbilt University
- State Bar of California
Rate : $$$